The 2017 Alternative Investment Awards Press Release

Bespoke Platform and Exchange for Hong Kong Fine Wine Investors www.wineowners.hk Opens 7th April 2014

Launching a crowdfunding campaign is a lot easier said than done. It takes a lot of effort before the launch, during the campaign and even after funding is complete.

Global firms could fail to capitalize on investments to boost innovation due to confidence issues in communication skills, according to a study by the Economist Intelligence Unit.

Native technology platform and network Adyoulike announces major UK acquisition to create European leader in native advertising

Do you want to learn about some of the best ways to get money online? If so, you have come to the right place! In this blog post, we will discuss 13 different methods that you can use to make money from home.  There are a number of ways to make extra money, and you […]

Yiannis Faf, CEO, What We Want The spread of coronavirus has caused an incredible amount of disruption to lives and economies worldwide. The British Government has taken far-reaching steps in an effort to minimise the impact on the UK in both regards, by encouraging the population to practise isolating. Such a massive overhaul of day-to-day […]

The CEO of one of the world’s largest independent financial advisory organisations expects a growing number of retirees to consider “higher risk-higher return investments”.

With household debt at an all-time high in America, it is understandable why people turn to loans to help them cover the cost of living. Taking out a loan can be a stressful situation, as you may have concerns about how and when you will be able to pay it all back.

Equinox Racing is a London based horse racing syndicate like no other. Focused on delivering immersive experience to its members, Equinox Racing recently opened its horse’s shares to cryptocurrency. From now on, you can use your Bitcoins to buy yourself the thrill of horse racing and the privilege of horse ownership.

NephroGenex, Inc., a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that it has commenced an underwritten public offering of shares of its common stock and expects to raise gross proceeds of up to $30 million. In addition, NephroGenex expects to grant the underwriters a 30-day option to purchase up to an additional $4.5 million of shares of its common stock in connection with the offering. All of the shares in the offering will be sold by NephroGenex.